Iovance Biotherapeutics, Inc. financial data

Symbol
IOVA on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
825 Industrial Road, 4 Th Floor, San Carlos, California
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Lion Biotechnologies, Inc. (to 6/5/2017), Genesis Biopharma, Inc (to 9/23/2013), FREIGHT MANAGEMENT CORP (to 3/8/2010)
Latest financial report
Q1 2024 - May 9, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 362 % -39.2%
Quick Ratio 12.6 %
Debt-to-equity 29.5 % -2.09%
Return On Equity -71.5 % +11.8%
Return On Assets -55.2 % +11.4%
Operating Margin -38.7K %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 280M shares +24.7%
Common Stock, Shares, Outstanding 280M shares +24.7%
Entity Public Float 1.4B USD -12.5%
Common Stock, Value, Issued 12K USD +33.3%
Weighted Average Number of Shares Outstanding, Basic 266M shares +24.6%
Weighted Average Number of Shares Outstanding, Diluted 266M shares +24.6%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 715K USD
Cost of Revenue 7.26M USD
Research and Development Expense 341M USD +10.3%
General and Administrative Expense 110M USD +1.27%
Costs and Expenses 469M USD +6.84%
Operating Income (Loss) -467M USD -11.8%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -455M USD -6.53%
Income Tax Expense (Benefit) -4.89M USD
Net Income (Loss) Attributable to Parent -450M USD -9.23%
Earnings Per Share, Basic -1.81 USD/shares +24.9%
Earnings Per Share, Diluted -1.81 USD/shares +24.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 134M USD -75.3%
Accounts Receivable, after Allowance for Credit Loss, Current 234K USD
Inventory, Net 17.6M USD
Assets, Current 386M USD -39.6%
Property, Plant and Equipment, Net 112M USD +1.7%
Operating Lease, Right-of-Use Asset 71.5M USD +1.54%
Other Assets, Noncurrent 259K USD +28.2%
Assets 870M USD +5.46%
Accounts Payable, Current 25.7M USD -18.6%
Accrued Liabilities, Current 46.4M USD +7.77%
Liabilities, Current 83.2M USD -4.65%
Deferred Income Tax Liabilities, Net 33.3M USD
Operating Lease, Liability, Noncurrent 72.3M USD +3.85%
Liabilities 190M USD +20.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax 116K USD
Retained Earnings (Accumulated Deficit) -2.13B USD -26.8%
Stockholders' Equity Attributable to Parent 680M USD +1.97%
Liabilities and Equity 870M USD +5.46%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -122M USD -22.5%
Net Cash Provided by (Used in) Financing Activities 194M USD -25%
Net Cash Provided by (Used in) Investing Activities -112M USD -173%
Common Stock, Shares Authorized 500M shares +66.7%
Common Stock, Shares, Issued 280M shares +24.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -40.7M USD -113%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 141M USD -74.4%
Deferred Tax Assets, Valuation Allowance 447M USD +27.5%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure
Deferred Tax Assets, Gross 464M USD +26.4%
Operating Lease, Liability 83.4M USD +1.39%
Depreciation 10.3M USD +129%
Payments to Acquire Property, Plant, and Equipment 4.17M USD -26.4%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -449M USD -9.76%
Lessee, Operating Lease, Liability, to be Paid 130M USD -2.25%
Property, Plant and Equipment, Gross 143M USD +10.4%
Operating Lease, Liability, Current 11.1M USD -12.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two 7.99M USD -3.05%
Lessee, Operating Lease, Liability, to be Paid, Year One 16.9M USD +59.7%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Deferred Income Tax Expense (Benefit) -1.41M USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 46.6M USD -8.17%
Lessee, Operating Lease, Liability, to be Paid, Year Three 8.19M USD +2.47%
Deferred Tax Assets, Operating Loss Carryforwards 256M USD +13.2%
Unrecognized Tax Benefits 26.1M USD +20.6%
Lessee, Operating Lease, Liability, to be Paid, Year Four 8.39M USD +2.48%
Operating Lease, Payments 17M USD +16.8%
Additional Paid in Capital 2.81B USD +19.7%
Amortization of Intangible Assets 14.5M USD
Depreciation, Depletion and Amortization 11.8M USD +14.6%
Deferred Tax Assets, Net of Valuation Allowance 17.6M USD +2.91%